Glenn Short, Ph.D., is Vice President of Early Development at atai Life Sciences where he works with atai’s portfolio companies to advance discovery, preclinical, and early clinical stage assets into clinical development. Dr. Short has 15 years of industry and research experience and has been involved in numerous programs that leverage cutting-edge biotechnologies to develop new therapies to address unmet medical needs in oncology, immunology, neurological disease, and pain.
Early in his research career, he discovered and patented a novel drug class of Nav1.7 ion channel antagonists that selectivity inhibited a confirmation of the ion channel involved in promoting pain signaling. Dr. Short most recently managed research and early clinical development programs for Flex Pharma as VP of Research and Translational Development focused on therapies to minimize spasticity, muscle spasms, and cramping in patients with multiple sclerosis, ALS, and peripheral neuropathy. In addition to Flex Pharma, Dr. Short held senior R&D positions at Axial Biotherapeutics, Zalicus, and CombinatoRx.
Dr. Short graduated from the University of Virginia with a B.A. degree in Chemistry and a Ph.D. in Bioorganic Chemistry and conducted his postdoctoral training in Molecular Biology at Massachusetts General Hospital/Harvard Medical School in Boston.